This postmarketing study was conducted to describe prescribing patterns for etoricoxib (ARCOXIA®) in General Practice and describe the incidence of selected adverse events recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency (MHRA) General Practice Research Database (GPRD).
Study Type
OBSERVATIONAL
Enrollment
79,189
As per routine clinical practice in the United Kingdom
Dose of Initial Etoricoxib Prescription
Time frame: At first prescription (during a time period up to 13.75 years)
Duration of Initial Etoricoxib Prescription
Time frame: At first prescription (during a time period up to 13.75 years)
Participant's Baseline Characteristics (Demographics and Medical)
Time frame: At first prescription (during a time period up to 13.75 years)
Incidence of Adverse Events of Special Interest Among Etoricoxib Users
Time frame: During a time period up to 13.75 years
"Off-label" use of Etoricoxib
Time frame: At first prescription (during a time period up to 13.75 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.